Completed phase I trials of FAK inhibitors in multiple solid tumors show promise54, and phase I/Ib trials of FAK inhibitors with Taxol are currently underway in patients with advanced ovarian cancer (NCT01778803). Here, PTK2 is linked to ovarian cancer.